Click here for slides on this topic


Continuous subcutaneous insulin infusion (CSII)

The use of a battery-powered pump system to deliver insulin into body via a needle or catheter placed in the subcutaneous tissue. It can be used by patients with type 1 diabetes as an alternative to daily injections of insulin. See insulin pump.
The following content matched the glossary term: Continuous subcutaneous insulin infusion (CSII)

AACE 2015 guidelines Diabetes & Pregnancy

Top

Summary of recommendations for gestational diabetes mellitus (GDM) from the 2015 AACE guidelines 

Endocrine Society Guideline on Diabetes and Pregnancy - Glycemic Targets & Glucose Management

Top

Diabetes Management Guidelines Endocrine Society Guideline on Diabetes and Pregnancy   Source Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013 98(11) 4227 4249. Available here.Refer to

American Diabetes Association 72nd Scientific Sessions Daily Coverage June 10, 2012

Top

Daily coverage from the American Diabetes Association 72nd Scientific Sessions June 10, 2012

Beta-cell function preservation, ACCORD-BP, update on insulin therapies for diabetes treatment, pharmacology for diabetes prevention, and more. 

Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes

Top

Colquitt JL, Green C, Sidhu MK, Hartwell D, Waugh N. Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes. Health Technol Assess. 2004;8:1-186. OBJECTIVES: To assess the clinical and cost-effectiveness of continuous subcutaneous insulin infusion (CSII) compared with multiple daily injections (MDI) in the delivery of intensive insulin therapy for the treatment of diabetes mellitus.

A Comparison of Troglitazone and Metformin on Insulin Requirements in Euglycemic Intensively Insulin-Treated Type 2 Diabetic Patients

Top

Yu JG, Kruszynska YT, Mulford MI, Olefsky JM .A Comparison of Troglitazone and Metformin on Insulin Requirements in Euglycemic Intensively Insulin-Treated Type 2 Diabetic Patients. Diabetes. 1999;48:2414-2421.To compare the insulin-sparing actions of troglitazone and metformin and their effects on insulin sensitivity and insulin secretion in 20 patients with type 2 diabetes.



Slide Library Results

Search Results for: Continuous subcutaneous insulin infusion (CSII) Slides Found: 1
AACE 2015 Guidelines Treating Gestational Diabetes GDM PPT | NDEI